Publications by authors named "J Mulliken"
Article Synopsis
- Infantile hemangioma (IH) is the most common tumor in children, primarily treated with propranolol, which affects blood vessel formation through a specific mechanism involving a protein called SOX18.
- Recent research identified the mevalonate pathway (MVP) as a target of propranolol, highlighting its role in the formation of hemangiomas and confirming this through studies on stem cells from hemangiomas.
- The study suggests that statins, which also target the MVP, could be repurposed to treat IH, revealing a new regulatory axis (SOX18-MVP) that may influence other conditions related to abnormal blood vessel growth.
Background: Infantile hemangioma (IH) is a benign vascular tumor that undergoes an initial rapid growth phase followed by spontaneous involution. A fibrofatty residuum remains in many tumors and often necessitates resection. We recently discovered that R(+) propranolol, the non-β blocker enantiomer, inhibits blood vessel formation of IH patient-derived hemangioma stem cells (HemSC) xenografted in mice.
View Article and Find Full Text PDFInfantile hemangioma (IH) is a benign vascular tumor that occurs in 5% of newborns. The tumor follows a life cycle of rapid proliferation in infancy, followed by slow involution in childhood. This unique life cycle has attracted the interest of basic and clinical scientists alike as a paradigm for vasculogenesis, angiogenesis, and vascular regression.
View Article and Find Full Text PDFObjective: To determine if the elastic chain premaxillary retraction (ECPR) appliance increases inter-medial and inter-lateral canthal dimension in patients with bilateral complete cleft lip and palate (BCLP).
Design: Retrospective cohort study.
Setting: Specialized tertiary care facility.